Skip to main content

Table 3 Potential new ductal carcinoma in situ susceptibility loci

From: Genetic predisposition to ductal carcinoma in situ of the breast

Single nucleotide polymorphism rs12631593 rs13236351 rs73179023
Chromosome 3 7 22
Position 60701884 97772513 43424477
Locus FHIT LMTK2 PACSIN2:TTLL1
Minor allele frequency 0.11 0.032 0.13
ICICLE DCIS phase I   
Odds ratio (95 % CI) 1.15 (1.04, 1.28) 1.31 (1.10, 1.56) 0.83 (0.75, 0.91)
P 0.0088 0.0029 0.00020
BCAC DCIS   
Odds ratio (95 % CI) 1.25 (1.14, 1.36) 1.3 (1.12, 1.51) 0.86 (0.79, 0.94)
P 1.0 × 10-6 0.00060 0.0012
Meta-analysis phase I   
Odds ratio (95 % CI) 1.21 (1.13, 1.29) 1.3 (1.16, 1.46) 0.85 (0.79, 0.90)
P 5.5 × 10-8 5.7 × 10-6 1.1 × 10-6
Phase II DCIS   
Odds ratio (95 % CI) 0.93 (0.76, 1.14) 0.91 (0.63, 1.31) 0.95 (0.78, 1.15)
P 0.49 0.61 0.57
Meta-analysis phase II   
Odds ratio (95 % CI) 1.18 (1.10, 1.25) 1.26 (1.13, 1.41) 0.86 (0.80, 0.91)
P 7.8 × 10-7 2.9 × 10-5 1.7 × 10-6
BCAC IDC   
Odds ratio (95 % CI) 1.01 (0.97, 1.05) 1.05 (0.99, 1.13) 0.97 (0.93, 1.00)
P 0.54 0.13 0.060
Case-only   
DCIS vs IDC P-Het 0.0048 0.17 0.0099
  1. DCIS ductal carcinoma in situ, IDC invasive ductal carcinoma, BCAC Breast Cancer Association Consortium, ICICLE Study to investigate the genetics of in situ carcinoma of the ductal subtype, P-Het P value for heterogeneity